Ashley M Polhemus1, Hassan Kadhim2, Shelly Barnes3, Susan E Zebrowski4, Alex Simmonds5, Shirley N Masand6, Jaclyn Banner7, Melissa Dupont8. 1. 1 MSD Global IT Innovation Center, Merck, Sharpe & Dohme Corp, Prague, Czech Republic. 2. 2 IT Clinical Trial Planning & Management, Boehringer Ingelheim, Ridgefield, CT, USA. 3. 3 Site and Patient Solutions, UCB Biosciences Inc, Raleigh, NC, USA. 4. 4 Technology Platform Operations, Shared Solutions, Janssen Research & Development, Malvern, PA, USA. 5. 5 Digital Clinical, R&D IT, Bristol-Myers Squibb, New York, NY, USA. 6. 6 Accenture Life Sciences, Berwyn, PA, USA. 7. 7 Clinical Data Management, Hoffmann-La Roche Limited, Mississauga, ON, Canada. 8. 8 Clinical Trial Operations, Sanofi, Bridgewater, NJ, USA.
Abstract
BACKGROUND: Patient-facing digital technologies (also called "Patient Technology" [PT]) have the potential to serve a variety of functions in clinical trials, such as capturing clinical endpoints, engaging patients, and facilitating remote study conduct. However, these technologies are not yet accepted as mainstream research tools, and the opportunities, challenges, and facilitators associated with their implementation in clinical trials have not been fully characterized. METHODS: In order to understand the factors affecting PT adoption, the TransCelerate Patient Technology Initiative conducted a series of surveys, interviews, and focus groups with approximately 600 subject matter experts, including pharmaceutical company representatives, clinical trial investigators at a number of trial sites worldwide, and clinical trial participants. All interview and survey responses were blinded and aggregated by a third-party consultant and themes were extracted. RESULTS: There was general consensus around the potential value of patient-facing technology as a clinical research tool, though a variety of challenges faced by each stakeholder were discussed. Detailed accounts of opportunities (improved patient experience, compliance, and engagement; clinical trial efficiencies; improved data quality and insights) and barriers (organizational and corporate cultural challenges, business-related challenges, user willingness and burden, and regulatory challenges) are reported. CONCLUSIONS: While the barriers to PT adoption explored here were numerous, they were also generally consistent. A number of proposals for establishing more holistic, collaborative, and strategic approaches to PT implementation in clinical trials are discussed. Such approaches could facilitate more effective, widespread adoption of PT, and thereby a more patient-centric clinical trial paradigm.
BACKGROUND:Patient-facing digital technologies (also called "Patient Technology" [PT]) have the potential to serve a variety of functions in clinical trials, such as capturing clinical endpoints, engaging patients, and facilitating remote study conduct. However, these technologies are not yet accepted as mainstream research tools, and the opportunities, challenges, and facilitators associated with their implementation in clinical trials have not been fully characterized. METHODS: In order to understand the factors affecting PT adoption, the TransCelerate Patient Technology Initiative conducted a series of surveys, interviews, and focus groups with approximately 600 subject matter experts, including pharmaceutical company representatives, clinical trial investigators at a number of trial sites worldwide, and clinical trial participants. All interview and survey responses were blinded and aggregated by a third-party consultant and themes were extracted. RESULTS: There was general consensus around the potential value of patient-facing technology as a clinical research tool, though a variety of challenges faced by each stakeholder were discussed. Detailed accounts of opportunities (improved patient experience, compliance, and engagement; clinical trial efficiencies; improved data quality and insights) and barriers (organizational and corporate cultural challenges, business-related challenges, user willingness and burden, and regulatory challenges) are reported. CONCLUSIONS: While the barriers to PT adoption explored here were numerous, they were also generally consistent. A number of proposals for establishing more holistic, collaborative, and strategic approaches to PT implementation in clinical trials are discussed. Such approaches could facilitate more effective, widespread adoption of PT, and thereby a more patient-centric clinical trial paradigm.
Authors: Diane Stephenson; Robert Alexander; Varun Aggarwal; Reham Badawy; Lisa Bain; Roopal Bhatnagar; Bastiaan R Bloem; Babak Boroojerdi; Jackson Burton; Jesse M Cedarbaum; Josh Cosman; David T Dexter; Marissa Dockendorf; E Ray Dorsey; Ariel V Dowling; Luc J W Evers; Katherine Fisher; Mark Frasier; Luis Garcia-Gancedo; Jennifer C Goldsack; Derek Hill; Janice Hitchcock; Michele T Hu; Michael P Lawton; Susan J Lee; Michael Lindemann; Ken Marek; Nitin Mehrotra; Marjan J Meinders; Michael Minchik; Lauren Oliva; Klaus Romero; George Roussos; Robert Rubens; Sakshi Sadar; Joseph Scheeren; Eiichi Sengoku; Tanya Simuni; Glenn Stebbins; Kirsten I Taylor; Beatrice Yang; Neta Zach Journal: Digit Biomark Date: 2020-11-26
Authors: Laurent Servais; Eric Camino; Aude Clement; Craig M McDonald; Jacek Lukawy; Linda P Lowes; Damien Eggenspieler; Francesca Cerreta; Paul Strijbos Journal: Digit Biomark Date: 2021-08-05
Authors: Amos J de Jong; Renske J Grupstra; Yared Santa-Ana-Tellez; Mira G P Zuidgeest; Anthonius de Boer; Helga Gardarsdottir Journal: BMJ Open Date: 2022-08-29 Impact factor: 3.006
Authors: Amos J de Jong; Tessa I van Rijssel; Mira G P Zuidgeest; Ghislaine J M W van Thiel; Scott Askin; Jaime Fons-Martínez; Tim De Smedt; Anthonius de Boer; Yared Santa-Ana-Tellez; Helga Gardarsdottir Journal: Clin Pharmacol Ther Date: 2022-05-17 Impact factor: 6.903
Authors: Marissa F Dockendorf; Bryan J Hansen; Kevin P Bateman; Matthew Moyer; Jyoti K Shah; Lisa A Shipley Journal: Clin Transl Sci Date: 2020-11-30 Impact factor: 4.689
Authors: Ashley Marie Polhemus; Jan Novák; Jose Ferrao; Sara Simblett; Marta Radaelli; Patrick Locatelli; Faith Matcham; Maximilian Kerz; Janice Weyer; Patrick Burke; Vincy Huang; Marissa Fallon Dockendorf; Gergely Temesi; Til Wykes; Giancarlo Comi; Inez Myin-Germeys; Amos Folarin; Richard Dobson; Nikolay V Manyakov; Vaibhav A Narayan; Matthew Hotopf Journal: JMIR Mhealth Uhealth Date: 2020-05-07 Impact factor: 4.773
Authors: Romée Melanie Helena Coert; James Kenneth Timmis; André Boorsma; Wilrike J Pasman Journal: J Med Internet Res Date: 2021-07-06 Impact factor: 5.428